Dimerix Limited (ASX:DXB)
Australia · Delayed Price · Currency is AUD 0.2500
-0.0100 (-3.85%)
Sep 10, 2026, 4:10 PM AEST
Dimerix Company Description
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia.
It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease; as well as DMX-652 for the treatment of acute kidney injury.
The company is headquartered in Fitzroy, Australia.
Contact Details
Address: 425 Smith Street Fitzroy, VIC 3065 Australia | |
| Phone | 1300 813 321 |
| Website | dimerix.com |
Stock Details
| Ticker Symbol | DXB |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000DXB7 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Nina Webster B.Sc., M.B.A., M.IP.Law, Ph.D. | Chief Executive Officer, MD and Director |
| Michael Tonroe ACA, B.Sc., Bsc(Hons), F.C.A., M.A.I.C.D. | Chief Financial Officer and Company Secretary |
| Dr. David Everett Fuller BPharm, M.D., MBBS | Chief Medical Officer |
| Kevin Donald George Pfleger BA (Hons), MA, Ph.D. | Chief Scientific Advisor |